• Financial forecast for 2009 reaffirmed)
• 2010 revenues expected to be between Euro 96 million and Euro 102 million
• 2010 EBIT margin expected to grow by more than 0.5% points over 2009
• 2010 to 2012 revenue CAGR expected to exceed 15%
• Free cash flow to fund planned expansion and further growth

Birkenfeld, December 17, 2009

STRATEC Biomedical Systems, Birkenfeld, Germany (Frankfurt: SBS; Prime Standard), has today published medium-term financial guidance based on recent clients’ forecasts and statements, allied to the Company’s current development pipeline. Current trading continues in line with management’s expectations, and STRATEC today reaffirms its previous guidance for 2009. As first detailed on April 8, 2009, guidance for 2009 calls for revenue growth of between 20% and 30% (Euro 73.2 million to Euro 79.3 million), and for an EBIT margin of between 18.5% and 19.5%.

For the financial year 2010, STRATEC expects sales in the range of Euro 96 million to Euro 102 million. The four major development programs ongoing and an increasing share of consumables and replacement parts will drive the EBIT margin. Management expects the EBIT margin to expand by more than 0.5% points over that achieved in 2009.

Based on the stable growth of all programs, as well as the prospects and forecasts for the new programs, STRATEC expects to continue its growth for the coming years. Specifically, the compound annual growth rate (CAGR) for sales over the years 2010 to 2012 is expected to exceed 15%.

“Our continuous growth trajectory is based on solid performance across all our major projects and on the development of new systems.” stated Hermann Leistner, CEO of STRATEC, adding: “Our leading position as an independent OEM supplier is strengthened by the continuous outsourcing trend in our industry as well as the strong demand for molecular diagnostics technologies and chemiluminescence assay analyzers. STRATEC’s state of the art technologies, such as random access analyzers, meet the requirements of our customers to offer solutions fitting the modern laboratory and blood bank workflows.”

In January 2010 STRATEC will present at the J.P. Morgan Global Healthcare Conference in
San Francisco, USA (January 11 - 14, 2010) and at the Cheuvreux German Corporate Conference in Frankfurt, Germany (January 18 - 20, 2010). For further conference participations please check STRATEC’s financial calendar at www.stratec-biomedical.de > Investor Relations > IR News > Financial Calendar.

About STRATEC

STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange, and are a constituent of the Deutsche Börse TecDAX.

The STRATEC Group consists of the publicly listed parent company STRATEC Biomedical AG and of subsidiaries and second-tier subsidiaries in Germany, the USA, the UK, Switzerland and Romania.

 

Further information can be obtained from:

STRATEC Biomedical AG
André Loy, Investor Relations
Gewerbestr. 37, 75217 Birkenfeld
Germany
Phone: +49 7082 7916 190
Fax: +49 7082 7916 999
Email:ir(at)stratec.com